Haloperidol - Pharmacology
Research News and Information

Saturday, November 21, 2009

In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.

20 Aug 2009 Control of the mesoaccumbens dopamine (DA) pathway by central serotonin(2C) receptors (5-HT(2C)Rs) involves different 5-HT(2C)R populations located within multiple brain areas. Here, using in vivo microdialysis in halothane-anesthetized rats, we ... Read more...

Examination of reinforcement magnitude on the pharmacological disruption of fixed-ratio performance.

30 Jul 2009 Behavioral momentum theory proposes that operant behavior is the product of two separable processes: its rate of occurrence and its resistance to change. Generally speaking, operant situations providing more densely spaced or greater magnitudes of ... Read more...

Effects of yokukansan, a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid beta protein into mice.

30 Jul 2009 The effects of yokukansan, a traditional Japanese medicine, on aggressiveness and motor activities were examined in mice after injection of amyloid beta protein (Abeta) into the lateral ventricle of the brain. The results were compared with those of ... Read more...

Latest indexed articles for 'Haloperidol - Pharmacology'

These are the very latest articles for this heading:

• In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. 20 Aug 2009
• Examination of reinforcement magnitude on the pharmacological disruption of fixed-ratio performance. 30 Jul 2009
• Effects of yokukansan, a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid beta protein into mice. 30 Jul 2009
• Long-term ventilatory adaptation and ventilatory response to hypoxia in plateau pika (Ochotona curzoniae): role of nNOS and dopamine. 27 Jul 2009
• Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. 29 Jun 2009
• Righting elicited by novel or familiar auditory or vestibular stimulation in the haloperidol-treated rat: rat posturography as a model to study anticipatory motor control. 22 Jun 2009
• Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. 10 Jun 2009
• Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine. 5 Jun 2009
• Effects of amphetamine on salivary secretion. 30 May 2009
• 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. 30 May 2009
• Targeting cognition in schizophrenia research: from etiology to treatment. 30 May 2009
• Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. 25 May 2009
• Effects of typical (haloperidol) and atypical (risperidone) antipsychotic agents on protein expression in rat neural stem cells. 18 May 2009
• Effects of the antipsychotic drug haloperidol on the somastostatinergic system in SH-SY5Y neuroblastoma cells. 9 May 2009
• The anti-dopaminergic agent, haloperidol, antagonises the feminising effect of neonatal serotonin on sexually dimorphic hypothalamic nuclei and tyrosine hydroxylase immunoreactive neurones. 5 May 2009
• N-4-tert-butyl benzyl haloperidol chloride suppresses Ca2+-dependent Egr-1 expression and subsequently inhibits vascular smooth muscle cell proliferation induced by angiotensin II. 4 May 2009
• Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. 29 Apr 2009
• Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral study. 29 Apr 2009
• A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol. 26 Apr 2009
• Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia. 21 Apr 2009

See a longer list of these articles.

Technical information about 'Haloperidol'

Definition: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in MENTAL RETARDATION and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)

Chemical name: 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-

Registry Number: 52-86-8

Descriptor UI: D006220

Alternative terms: Haloperidol; Haldol;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiemetics; Antipsychotic Agents; Dopamine Antagonists; Anti-Dyskinesia Agents;

Tree Number: D02.522.352.506;